Mishra Anurag, Castañeda Tamara R, Bader Erik, Elshorst Bettina, Cummings Sheila, Scherer Petra, Bangari Dinesh S, Loewe Claudia, Schreuder Herman, Pöverlein Christoph, Helms Mike, Jones Seth, Zech Gernot, Licher Thomas, Wagner Michael, Schudok Manfred, de Hoop Meltsje, Plowright Alleyn T, Atzrodt Jens, Kannt Aimo, Laitinen Iina, Derdau Volker
Industriepark Höchst 65926 Frankfurt Germany.
R&D Diabetes Sanofi-Aventis Deutschland GmbH Industriepark Höchst 65926 Frankfurt Germany.
Adv Sci (Weinh). 2020 Nov 9;7(24):2002997. doi: 10.1002/advs.202002997. eCollection 2020 Dec.
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease that can lead to irreversible liver cirrhosis and cancer. Early diagnosis of NASH is vital to detect disease before it becomes life-threatening, yet noninvasively differentiating NASH from simple steatosis is challenging. Herein, bifunctional probes have been developed that target the hepatocyte-specific asialoglycoprotein receptor (ASGPR), the expression of which decreases during NASH progression. The results show that the probes allow longitudinal, noninvasive monitoring of ASGPR levels by positron emission tomography in the newly developed rat model of NASH. The probes open new possibilities for research into early diagnosis of NASH and development of drugs to slow or reverse its progression.
非酒精性脂肪性肝炎(NASH)是一种非酒精性脂肪性肝病的进展形式,可导致不可逆转的肝硬化和癌症。NASH的早期诊断对于在疾病变得危及生命之前进行检测至关重要,然而,通过非侵入性方法区分NASH和单纯性脂肪变性具有挑战性。在此,已开发出靶向肝细胞特异性去唾液酸糖蛋白受体(ASGPR)的双功能探针,在NASH进展过程中其表达会降低。结果表明,这些探针能够在新建立的NASH大鼠模型中通过正电子发射断层扫描对ASGPR水平进行纵向、非侵入性监测。这些探针为NASH的早期诊断研究以及开发减缓或逆转其进展的药物开辟了新的可能性。